OncLive TV

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Zeynep Eroglu, MD, discusses the utilization of circulating tumor DNA in patients with melanoma.

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer.

Mohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

Brad S. Kahl, MD, discusses the potential for zanubrutinib in the frontline treatment of chronic lymphocytic leukemia.

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Benjamin H. Lowentritt, MD, FACS, discusses the real-world analysis of apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer.

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Kathleen Moore, MD, discusses current standard of care in treating ovarian cancer.

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer.